Trials / Completed
CompletedNCT00051116
A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Celgene Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the response rate, response duration, and survival of patients treated with CC-5013 in a chronic dosing schedule versus a syncopated dosing schedule.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CC-5013 |
Timeline
- Start date
- 2002-05-01
- Primary completion
- 2006-10-01
- Completion
- 2006-10-01
- First posted
- 2003-01-07
- Last updated
- 2009-09-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00051116. Inclusion in this directory is not an endorsement.